BIOCIUS Life Sciences Extends Global Presence with Distribution Agreement for Japan

BIOCIUS Life Sciences Extends Global Presence with Distribution Agreement for Japan

Wako Pure Chemical Industries to Exclusively Distribute RapidFire® in Japan

Woburn, MA., USA and Osaka, JAPAN; March 3rd, 2010. BIOCIUS Life Sciences Inc., developers of the RapidFire® high‐throughput mass spectrometry system, today announced an exclusive distribution agreement for the Japanese market with Wako Pure Chemical Industries, Ltd. Wako will distribute the label‐free RapidFire product and contract research services portfolio for lead discovery and in vitro ADME screening applications, including the recently launched RF300 system.

“Japan is an important market for pharmaceutical discovery and as a premier distributor in Japan, we strongly believe that Wako is the right partner to provide our portfolio to this dynamic sector,” said Jeffrey Leathe, President and Chief Executive Officer of BIOCIUS Life Sciences. “In 2009 we expanded geographically, installing several systems outside of the United States, across Europe and Canada; we are looking forward to working with Wako, a company that has a great market presence and reputation in the industry to further expand our reach throughout Japan.”

BIOCIUS’s RapidFire technology makes mass spectrometry‐based screening economically viable by providing label‐free, biologically relevant data at high throughputs. At an analysis time of six to eight seconds per sample, RapidFire enables drug discovery researchers to decrease their screening bottlenecks and more efficiently utilize resources. Under the terms of the agreement, Wako Pure Chemical Industries will offer both RapidFire instrumentation and contract research services in Japan. According to Haruki Oishi, Ph.D., General Manager, BioMedical Systems Department, “At Wako, we see
a tremendous opportunity for RapidFire in Japan; we feel BIOCIUS’s technologies will enable us to provide our customers with drug discovery solutions through the synergy with Wako’s product line and a means to investigate therapeutic targets that have been difficult to analyze by conventional methods.” Wako will fully support the technology in Japan with a team of expert application scientists and field support engineers.

About BIOCIUS Life Sciences, Inc.

Named from the Greek word “BIO” (life) and the Latin word “OCIUS” (faster), BIOCIUS Life Sciences, provides the biopharmaceutical industry with faster answers: Products and services committed to speed and accuracy in drug discovery. Used by 13 of the top 15 pharmaceutical companies, BIOCIUS’s products and contract research services enable our partners to exceed their business goals.

About Wako Pure Chemicals

Founded in 1922, Wako Pure Chemical Industries, Ltd. has been engaged in the development and manufacture of high‐quality products as a comprehensive reagent manufacturer capable of responding to research needs in cutting‐edge areas. At present, Wako uses its unique technological capabilities to focus on three key operational areas, namely: Laboratory Chemicals, Specialty Chemicals and Diagnostic Reagents, and to meet the diverse requirements of researchers, medical professionals and industry. The core competence of Wako Pure Chemical Industries, Ltd. lies in its technological strength, which creates innovative products of the highest quality. Wako utilizes its unique technological capabilities to progress as a global corporation. In addition to overseas production carried out under a stringent management system, Wako implements technological and sales partnerships, import‐export and other various international activities.


Jennifer M. Rossi, Ph.D.
Director of Marketing & Corporate Communications

Haruki Oishi, Ph.D.
General Manager for Biomedical Systems Department
web site http://www.wako‐


Contact Info

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184